John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Opinion|Videos|February 28, 2026
Matthew Galsky, MD, on infrastructure and education in BCG/ICI integration
Author(s)Matthew Galsky, MD
Fact checked by: Hannah Clarke, Tracy Ann Politowicz
Matthew D. Galsky, MD, discusses what is needed for successful integration of BCG/ICI combinations in BCG-naive non–muscle invasive bladder cancer.
Advertisement
In the following video, Matthew D. Galsky, MD, emphasizes that the successful integration of BCG/immune checkpoint inhibitor (ICI) combinations in BCG-naive non–muscle invasive bladder cancer (NMIBC) will depend on logistics, infrastructure, team education, and a coordinated recognition of immune-related adverse events across urology and oncology practices. Galsky is a professor of medicine at the Icahn School of Medicine at Mount Sinai and the director of GU medical oncology at the Tisch Cancer Center in New York, New York.
Advertisement
Related to this article
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Eugene Cone, MD, discusses recombinant BCG for NMIBC, including ongoing clinical evaluation and its potential to address ongoing BCG supply challenges.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
3
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
4
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
5